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Abstract 
Recently, gain-of-function (GOF) mutations in the gene encoding signal transducer 
and activator of transcription 1 (STAT1) have been associated with chronic 
mucocutaneous candidiasis (CMC). This case report describes a 10-year-old boy 
presenting with signs of common variable immunodeficiency (CVID), failure to 
thrive, impaired neurological development, and a history of recurrent 
mucocutaneous Candida infections. Sequencing of the STAT1 gene identiﬁed a 
heterozygous missense mutation in exon 7 encoding the STAT1 coiled-coil domain 
(c.514T>C, p.Phe172Leu). In addition to hypogammaglobulinemia with B-cell 
deficiency, and a low percentage of Th17 cells, immunological analysis of the 
patient revealed a marked depletion of forkhead-box P3+-expressing regulatory T 
cells (Tregs). In vitro stimulation of T cells from the patient with interferon-α (IFNα) 
and/or IFNɣ resulted in a significantly increased expression of STAT1-regulated 
target genes such as MIG1, IRF1, MX1, RIG-G, MCP1/CCL2, IFI-56K, and CXCL10 
as compared to IFN-treated cells from a healthy control, while no IFNα/ɣ-mediated 
up-regulation of the FOXP3 gene was found. These data demonstrate that the 
STAT1 GOF mutation F172L, which results in impaired stability of the antiparallel 
STAT1 dimer conformation, is associated with inhibited Treg cell development and 
neurological symptoms.    
 
Introduction 
Growing evidence suggests that several single point mutations in the gene 
encoding the human transcription factor STAT1 (signal transducer and activator of 
transcription 1) result in impaired interleukin-17 (IL-17) immunity causing chronic 
mucocutaneous candidiasis (CMC) (Liu et al. 2011; van de Veerdonk et al. 2011; 
Hori et al. 2012; Takezaki et al. 2012; Aldave et al. 2013; Soltesz et al. 2013). As 
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recently described, gain-of-function (GOF) mutations in the human STAT1 gene not 
only cause CMC, but can also present with a variety of other clinical phenotypes 
due to immune dysregulation, such as intracellular dimorphic fungal (histoplasmosis 
and disseminated coccidioidomycosis), atypical mycobacterial infections and the 
wild-type forkhead-box protein 3 (FOXP3) immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX)-like syndrome (Uzel et al. 2013; 
Sampaio et al. 2013; Kumar et al. 2014; Depner et al. 2015).  
The majority of autosomal dominant, CMC-causing mutations are located at the 
interface between the two protomers of the antiparallel STAT1 dimer, which is 
formed through reciprocal binding of the coiled-coil domain of one protomer to the 
DNA-binding domain of its partner protomer (Zhong et al. 2005; Mertens et al., 
2006; Wenta et al., 2008). Numerous studies have established that mutations 
affecting the stability of the antiparallel STAT1 dimer conformation result in reduced 
numbers of IL-17-producing CD4+ T cells (Liu et al. 2011; Smeekens et al., 2011; 
van de Veerdonk et al. 2011; Takezaki et al. 2012; Soltesz et al. 2013). However, 
much less is known about the formation of regulatory T cells (Treg) in response to 
stimulation of cells with interferon. In this case report, we describe the clinical and 
laboratory findings in a STAT1-F172L mutation carrier, presenting with clinical 
features of CMC who exhibited low numbers of Tregs and a promoter-specific up-
regulation of STAT1-driven target genes. 
 
Methods 
Peripheral blood samples were taken from the patient and a healthy age- and sex-
matched donor after informed consent. For phenotypic characterization, 50 µl of 
whole blood were incubated with antibody mixtures for 45 min and subsequently 
fixed and washed before analysis. The antibodies used were anti-CD3 (clone 
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OKT3), anti-CD4 (clones RPA-T4 or SK3), anti-CD8 (clone RPA-T8; eBioscience), 
anti-CD25 (clone 2A3; BD Biosciences), anti-CD127 (clone HCD127), anti-CD45RA 
(clone H100), anti-CCR7 (clone TG8), anti-IL-17 (clone BL168), anti-IFNɣ (clone 
4S.B3; eBioscience), and anti-FOXP3 (clone 259D). All antibodies were purchased 
from BioLegend, if not stated otherwise. Tregs were identified as 
CD4+CD25+CD127lo or as CD4+FOXP3+, in surface or intracellular stainings, 
respectively. Blood cells were first stained for cell surface molecules and then fixed 
and permeabilized with the appropriate buffer before being stained with anti-
FOXP3. For detection of intracellular cytokines, 1x106 PBMC were stimulated for 5 
h with 50 ng/ml phorbol myristate acetate, 1 µg/ml ionomycin and IL-2 (50 U/ml; 
Novartis; A2542) in the presence of brefeldin A. After incubation, the samples were 
stained first with antibodies against surface molecules CD3 (BD; 345766), CD4 
(Beckman Coulter; 737660), and CD45R0 (BD; 562299). Cells were fixed, 
permeabilized (BD Cytofix/Cytoperm) and stained for intracellular IFNɣ (BD; 
554700), and IL-17 (eBioscience; 12-7179-42). For intracellular phospho-STAT1 
staining, mononuclear cells were left either untreated or treated with IFNα (1000 
U/ml; Miltenyi Biotec) or IFNɣ (200 ng/ml; Miltenyi Biotec) for 15 min. For detection 
of phospho-STAT3, cells were stimulated with IL-21 (100 ng/ml; Miltenyi Biotec) 
before fixation. Cells were then fixed for 10 min (Phosflow Lyse/fix buffer; BD) and 
stained for CD14 (IM0645U; Beckman Coulter), followed by permeabilization for 30 
min (Perm III buffer; BD). Cells were additionally stained for P-STAT1 (612597; BD). 
To assess proliferation, freshly prepared PBMC were labeled with eFluor 670 
(eBioscience) according to the manufacturer’s protocols and cultured with 1 µg/ml 
soluble anti-CD3 (clone OKT3; BioXcell) and 20 U/ml of IL-2. On days 3 and 4, cells 
were stained with anti-CD4 and anti-CD8 antibodies, and eFluor 670 dilution was 
measured by flow cytometry. All samples were analyzed in a FACS Canto II flow 
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cytometer using the FACSDiva software (BD Biosciences) or in a Navios cytometer 
(Beckman Coulter). Expression of STAT1-regulated target genes in T cells was 
assessed by means of real-time PCR. Briefly, after RNA isolation and cDNA 
synthesis from isolated T cells, each real-time PCR reaction was measured in 
duplicate in a total volume of 20 µl, containing 1 µl of cDNA, 70 nmol/l of each 
primer, and 10 µl of Absolute Blue QPCR SYBR Green mix (Thermo Scientific). The 
following gene-specific primers for IFNα-inducible genes (MX1, RIG-G, and IFI-56K) 
were used:  MX-1F: 5´-CAATCAGCCTGCTGACATTG-3´, MX-1R: 5´-
TGTCTCCTGCCTCTGGATG-3´, RIG-GF: 5´-CAGAAGCCCAGACTTACCTG-3´, 
RIG-GR: 5´-ATAGGCAGAGATCGCATACC-3´, IFI-56KF: 5´-
TAGCCAACATGTCCTCACAGAC-3´, and IFI-56KR: 5´-
TCTTCTACCACTGGTTTCATGC-3´. Primers used for IFNɣ-inducible genes as well 
as for STAT1 and GAPDH were as previously described (Staab et al., 2013). The 
relative expression of a transcript was normalized to the expression of  GAPDH as 
determined for each sample. The Ct-method was used to determine comparative 
relative expression levels. To compare gene expression data, unpaired Student's t 
or Mann-Whitney U tests were used, and differences were considered significant if 
p ≤ 0.05. 
 
Results 
Case representation 
A 10-year-old boy of non-consanguineous, healthy parents was referred to our 
hospital because of abdominal bloating and pain, diarrhea, weight loss and fatigue. 
His medical history revealed multiple Candida infections of the skin (face and limbs) 
and recurrent infections of the upper respiratory tract with frequent wheezing since 
early childhood, including one episode of hospital-treated pneumonia. Despite 
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elevated serum gliadin IgG antibodies, endoscopy showed no histological signs of 
celiac disease, but severe ulcerative, microbiologically confirmed Candida albicans 
esophagitis. Physical examination showed severe dystrophy (height and weight 
below the 3rd percentile), while endocrinological work-up showed no deficiency of 
growth hormone. Standardised neuropsychological tests demonstrated delayed 
development of speech and interllectual ability, impaired short-time memory, and a 
marked attention-deficit disorder.  
 
Laboratory findings  
Laboratory results included anaemia (haemoglobin 9.6 g/dL), 
hypogammaglobulinemia and an impaired antibody production against routine 
vaccinations (diphtheria and tetanus). The screening test for HIV1/2 was negative. 
The patient had persisting B-cell lymphopenia with an increased proportion of naive 
(IgM+IgGD+CD27-), CD21low- and transitional B cells, while marginal-zone-like cells 
(IgD+CD27+IgM) and switched memory B and plasma cells (IgD-CD27+) were 
reduced. With low serum levels of IgG, IgA and IgM and a diminished response to 
vaccines, the patient fulfilled diagnostic criteria for common variable 
immunodeficiency (CVID). FACS-based functional assays demonstrated a reduction 
of IL-17 expression on CD4+/CD45RO+ T cells (Fig. 1A). In vitro T-cell assays 
showed that Candida antigen stimulation resulted in a decreased IFNɣ response, 
while the response after phorbol myristate acetate (PMA) stimulation was high in 
CD4+ T cells. The distribution of V beta receptor chains on CD4+ and CD8+ T cells 
appeared to be normal. In IFNα- and IFNɣ-stimulated monocytes from blood 
samples of the index patient, a significantly increased level of tyrosine-
phosphorylated STAT1 was observed as compared to monocytes from a healthy 
control (Fig. 1B). However, the level of IL-21-induced phospho-STAT3 activation did 
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not differ between control and patient (Fig. 1C) 
 
Genetic findings   
Using DNA sequencing, we identified a rare de novo (parents had wild-type 
genotype) heterozygous mutation (c.514T>C, p.Phe172Leu) in exon 7 of the STAT1 
gene, resulting in an amino acid exchange in the coiled-coil domain (Fig. 1D). 
Sanger sequencing showed no evidence of CVID-associated genetic alterations in 
any of the following genes tested: BTK, IGHM, IGLL1, CD79A, CD79B, BLNK, 
ICOS, CD19, CD81, TNFRSF13B (TACI), and TNFRSF13C (BAFFR). In addition, 
endocrinopathy candidiasis ectodermal dystrophy (APECED) was excluded by 
sequencing the AIRE gene (Kisand et al. 2010). Moreover, FOXP3 was wild-type.  
 
Detection of regulatory T cells and gene expression 
FACS analysis using FOXP3 staining revealed a low percentage of Tregs 
(Foxp3+CD25+CD4+ T cells) as compared to control (1.9% vs 5.8%) (Fig. 2A). CD4+ 
T cells showed normal up-regulation of the α-chain of the IL-2 receptor CD25 and 
proliferation in response to polyclonal stimulation (Fig. 2B). Upon in vitro stimulation 
of T cells with either IFNα and/or IFNɣ for 6 hours, we found a markedly increased 
expression of MIG1, MX1, RIG-G, MCP1, IFI-56K, IRF1, and CXCL10 genes (Fig. 
3). Although the STAT1 gene was significantly up-regulated by both IFNα and 
IFNɣtreatment, indicative of a positive feed-back loop, we found no difference in the 
expression level between cells from the patient carrying the GOF mutation and the 
healthy control.  
 
Clinical course 
Medical history, clinical presentation, and results from laboratory tests led to the 
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clinical diagnosis of chronic mucocutaneous candidasis (CMC) with common 
variable immunodeficiency (CVID), and treatment with prophylactic fluconazol, 
trimethoprim/sulfmethoxazole and intravenous immunglobulins (IVIG) was initiated. 
During the following months, the clinical condition of the child improved and his 
susceptibility to upper respiratory infections declined, although he still suffered from 
several episodes of oral candidiasis, aphthous stomatitis and bacterial 
keratoconjunctivitis.  
 
Discussion 
In the present case report, we describe the phenotype of a 10-year-old boy 
presenting with recurrent mucosal Candida infections, failure to thrive and cognitive 
retardation, in whom we identified a heterozygous mutation (c.514T>C, 
p.Phe172Leu) in STAT1. Immunological investigations using the patient´s immune 
effector cells clearly demonstrated a selective T-cell defect with Th17 deficiency and 
a B-cell deficiency with hypogammaglobulinemia. Despite the fact that severe CMC 
could initially be controlled with fluconazole prophylaxis and additional supportive 
treatment, including antibiotic prophylaxis and intravenous immunoglobulin (IVIG) 
infusions, our patient still suffers from a severe clinical phenotype with dystrophy 
and delayed neurocognitive development. A similar mutation has been described in 
a 25-year-old woman born to non-consanguineous parents without a family history 
of fungal infections or autoimmunity, who presented with disseminated and 
relapsing histoplasmosis in childhood and later developed chronic and recurrent 
oral, cutaneous and vaginal candidiasis (Sampaio et al. 2013).  
The phenylalanine residue at position 172 in the STAT1 coiled-coil domain binds 
with its aromatic side chain to a pocket in the DNA-binding domain of the partner 
protomer located at the dimer interface which is required for the formation of 
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antiparallel homodimers (Zhong et al. 2005; Mertens et al., 2006; Staab et al. 2013) 
(Fig. 1D). Due to steric hindrance, substitution of either leucine or tryptophan for 
phenylalanine critically impairs the stability of the antiparallel dimer conformation 
and shifts the equilibrium to the parallel conformation. In the parallel conformer, the 
SH2 domains of the two protomers are located on the same site of the dimer and 
interact reciprocally via their phosphorylated tyrosine residues 701. Since the 
STAT1-inactivating tyrosine phosphatase Tc45 acts exclusively on the antiparallel 
dimer, a shift towards the parallel dimer conformation results in a reduced rate of 
tyrosine dephosphorylation and, consequently, enhanced induction of numerous 
IFN-driven target genes.  
The clinical features of hypogammaglobulinaemia and B-cell lymphopenia found in 
our patient are not typical in CMC patients. In accordance with defective B-cell 
function, antibody production against routine vaccines such as diphtheria and 
tetanus was impaired. As described above, defects in BTK, IGHM, IGLL1, CD79A, 
CD79B, BLNK, ICOS, CD19, CD81, TNFRSF13B (TACI), and TNFRSF13C (BAFF-
R) that could explain the immunodeficiency in our patient have been excluded (Al-
Herz et al. 2014). Recently, Romberg et al. (2013) reported on individuals of a 
family with a complex clinical phenotype including candidiasis, humoral 
immunodeficiency with hypogammaglobulinaemia and B-cell lymphopenia caused 
by increased B-cell apoptosis with overexpression of protein ligand 1 (PD-L1).  
The pathways behind the reduced expansion of Tregs in our patient are currently 
unknown. Recently, Gurram and colleagues reported that treatment with the 
antifungal agent caerulomycin A resulted in the generation of Tregs by suppressing 
IFNɣ-driven STAT1 signalling via expression of its inhibitor SOCS1 (suppressor of 
cytokine signalling 1) (Gurram et al. 2013). Goodmann et al. (2011) demonstrated 
that the relative levels of activated STAT1 and its homolog STAT3 regulate the 
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effectiveness of Treg mechanisms. In the presence of highly phosphorylated STAT1, 
activation of STAT3 resulted in Tregs suppression, while this suppression was 
impaired in cells expressing low levels of activated STAT1. In a model of bone 
marrow transplantation, Ma et al (2011) showed that lack of STAT1 expression in 
donor splenocytes attenuated morbidity and mortality in graft-versus-host disease 
(GVHD) and resulted in the expansion of CD4+CD25+Foxp3+ donor T cells in vivo. 
The absence of STAT1 enhanced the generation of inducible Tregs by promoting 
their proliferation and inhibiting apoptosis of natural Tregs. However, in the case of 
hyperactive STAT1, this may inversely lead to low cell numbers and reduced 
expansion of Tregs, as was observed in our CVID patient with a dimer-specific GOF 
mutation.  
In summary, a missense mutation in the STAT1 gene affecting the structural stability 
of the antiparallel dimer formation results in a complex clinical phenotype including 
recurrent episodes of CMC, impaired neurocognitive development, and severe 
CVID. Despite unaltered proliferation of T cells in response to stimulation with anti-
CD3 and IL-2, we found evidence of a reduced number of Treg cells, as judged by 
decreased FOXP3 staining. These clinical observations underscore the central role 
of STAT1 in T cell development and both cellular and humoral immunity. 
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Figure legends 
Figure 1: Phenotypic and functional properties of lymphocytes and monocytes are 
indicative of STAT1 GOF. (A) Freshly isolated PBMC from the patient and a healthy 
control were stimulated with PMA/ionomycin in the presence of Brefeldin A for 5 h 
prior to intracellular staining for IL-4, IL-17 and IFNγ (normal values: IFNγ+ of 
CD4+/CD45R0+: 16.4-32.6%; IL-17+ of CD4+/CD45R0+: 1.1-4.7%). (B) Stimulation of 
monocytes with IFNα (500 U/ml) or IFNɣ (500 ng/ml) for 15 min followed by fixation, 
permeabilization and intracellular staining for tyrosine-phosphorylated STAT1 (P-
STAT1) showed increased STAT1 phosphorylation in the patient´s monocytes. (C) 
Similar pattern of IL-21-induced STAT3 phosphorylation in lymphocytes from a 
healthy control and the patient. (D) Crystal structure of a truncated STAT1 dimer 
showing the localization of the aromatic side chain of the critical phenylalanine 
residue 172 in the coiled-coil domain which is required for the formation of an 
antiparallel conformer (marked in magenta, Mao et al. 2005). The DNA-binding 
domain within each protomer is highlighted in a different color. 
 
Figure 2: (A) FACS-based analysis demonstrating low percentages of regulatory T 
cells (1.9%) as compared to a healthy control (5.8%). (B) Normal proliferation and 
up-regulation of CD25 upon stimulation of CD4+ T cells with anti-CD3 and IL-2. 
 
Figure 3: Mean and standard deviation of real-time PCR data in isolated T cells from 
a healthy control and the patient showing gene-specific induction of STAT1-target 
genes before and after stimulation of T cells with IFNα, IFNɣ or a mixture of both 
cytokines. Relative gene expression was normalized to the expression of the 
housekeeping gene GAPDH.  
 
